Browse > Article

Radiation Therapy Combined with Cisplatin Based Chemotherapy for the Patients with Locally Advanced Nasopharyngeal Cancer  

Son, Seok-Hyun (Department of Radiation Oncology, Catholic University of Korea)
Kim, Ji-Yoon (Department of Radiation Oncology, Catholic University of Korea)
Kim, Sung-Whan (Department of Radiation Oncology, Catholic University of Korea)
Mun, Seong-Kwon (Department of Radiation Oncology, Catholic University of Korea)
Cho, Seung-Ho (Department of Otolaryngology, Catholic University of Korea)
Park, Young-Hak (Department of Otolaryngology, Catholic University of Korea)
Hong, Young-Seon (Department of Hemato-Oncology, Catholic University of Korea)
Kim, Yeon-Sil (Department of Radiation Oncology, Catholic University of Korea)
Publication Information
Korean Journal of Head & Neck Oncology / v.22, no.2, 2006 , pp. 123-129 More about this Journal
Abstract
Objective : This retrospective study was designed to evaluate the anti-tumor efficacy and toxicities of the radiation therapy(RT) combined with cisplatin-based chemotherapy in locally advanced nasopharyngeal cancer(NPC). Materials and Methods : Fifty three patients with locally advanced NPCs(AJCC stage II, III, IV) received curative RT and cisplatin-based chemotherapy. Duration of follow-up ranged from 5.5 to 201 months(median 50.8 months). Nineteen patients(35.8%) were treated with induction chemotherapy including cisplatin $100mg/m^2$ for 1 day and 5-fluorouracil $1g/m^2$ for 5 days followed by RT(Induction CTx-RT). Another 34 patients (64.2%) were treated with concurrent chemoradiation(CCRT) using cisplatin $100mg/m^2$(D1, 22, 43). Results : Thirty-six(67.9%) and 11(20.8%) patients achieved clinical complete response and partial response, respectively. The pattern of failure was as follows:14 locoregional recurrence(26.4%) and 7 distant metastasis(13.2%). Among them, two patients(3.8%) had both locoregional and distant failure. Median overall survival(OS) and progression-free survival(PFS) were 85.5 months and 87.5 months, respectively. Five-year OS rate was 57.1%. The stage(AJCC), tumor response to chemoradiation and T stage were significant prognostic factors for OS(p=0.0113, p=0.0362 and p=0.0469). The stage(AJCC), tumor response to chemoradiation were also significant prognostic factors for PFS(p=0.0329, p=0.0424). Compared to each treatment group(Induction CTx-RT vs. CCRT), there were no significant differences in OS and PFS(p=0.7000, p=0.8261). Grade 3-4 mucositis, nausea/vomiting and hematological toxicities were noticed in 35.8%, 11.3% and 13.2%, respectively. Delayed RT over 2 weeks was inevitable in 26.5%. Seventeen patients(50%) successfully completed planned 3 courses of cisplatin in CCRT group. Conclusions : RT combined with cisplatin-based chemotherapy in locally advanced NPC showed high response rate, good locoregional control, and survival rate. As expected, frequency of acute toxicities increased, and the patient's compliance to treatment was need to be improved. Although our data could not show additional survival benefit of CCRT compare to that of induction chemotherapy followed by RT, patients' accrual and further follow-up are required due to limitation of retrospective study.
Keywords
Nasopharyngeal cancer; Chemoirradiation; Cisplatin; Radiation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hareyama M, Sakata K, Shirato H, et al: A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer. 2002;94:2217-2223   DOI   ScienceOn
2 Yun SM, Kim JC, Park IK: Combined modality treatment in nasopharyngeal carcinoma. J Korean Soc Ther Radiol Oncol. 2001;19 (2 ):100-106   과학기술학회마을
3 Rossi A, Molinari R, Boracchi P, et al: Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in locoregional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol. 1988;6:1401-1410   DOI
4 Chan AC, Teo PL, Ngan RK, et al: Concurrent chemotherapyradiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002;20:2038-2044   DOI   ScienceOn
5 Ma J, Mai HQ, Hong MH, et al: Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19:1350-1357   DOI
6 Sanguinetti G, Geara FB, Garden AS, et al: Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys. 1997;37:985-996   DOI   ScienceOn
7 DeVita VT, Hellman S, Rosenberg SA: Cancer: Principles & Practice of oncology. $7^{th}$ ed. Philadelphia; Lippincott Williams & Wilkins, 2005:712-713
8 Chi KH, Chang YC, Guo WY, et al: A Phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2002;52:1238-1244   DOI   ScienceOn
9 Qin D, Hu Y, Yan J, et al: Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer. 1988;61:1117-1124   DOI   ScienceOn
10 Lin JC, Jan JS, Hsu CY, et al: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progressionfree survival. J Clin Oncol. 2003;21:631-637   DOI   ScienceOn
11 Chua DT, Sham JT, Choy D, et al: Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 1998;83:2270-2283   DOI   ScienceOn
12 Cvitkovic E and the International Nasopharynx Cancer Study Group: Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin ) plus radiotherapy vs. radiotherapy alone in stage IV $(>=N_2,\;M_0)$ undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys. 1996;35:463-469   DOI   ScienceOn
13 Al-Sarraf M, LeBlanc M, Giri PG, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16:1310-1317   DOI